Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.35 |
| ▸ | MAPK3 | P27361 | 4/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.34 |
| ▸ | CDK2 | P24941 | 5/20 | 0.34 |
| ▸ | CCNK | O75909 | 4/20 | 0.34 |
| ▸ | CDK9 | P50750 | 4/20 | 0.34 |
| ▸ | INSR | P06213 | 2/20 | 0.34 |
| ▸ | CCND3 | P30281 | 4/20 | 0.33 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.33 |
| ▸ | MET | P08581 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29661540 | 1.00 | MAP4K1 (0.35) | MAP4K1MAPK3ALKCCNA2CDK2 | |
| SCHEMBL24327605 | 0.80 | MAP4K1 (0.38) | MAP4K1ALKCCNA2CDK2CCNK | |
| SCHEMBL29661395 | 0.80 | MAP4K1 (0.38) | MAP4K1ALKCCNA2CDK2CCNK | |
| SCHEMBL29661304 | 0.76 | CCNA2 (0.38) | MAP4K1MAPK3ALKCCNA2CDK2 | |
| SCHEMBL24327015 | 0.76 | CCNA2 (0.38) | MAP4K1MAPK3ALKCCNA2CDK2 | |
| SCHEMBL24327013 | 0.73 | INSR (0.39) | MAP4K1ALKCCNA2CDK2CCNK | |
| SCHEMBL24327586 | 0.73 | IGF1R (0.35) | MAP4K1CCNA2CDK2CCNKCDK9 | |
| SCHEMBL29661346 | 0.73 | INSR (0.39) | MAP4K1ALKCCNA2CDK2CCNK | |
| SCHEMBL24327455 | 0.71 | IGF1R (0.35) | MAP4K1ALKCCNA2CDK2CCNK | |
| SCHEMBL24328293 | 0.71 | ALK (0.33) | MAP4K1ALKCCNA2CDK2CCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| CN-116249690-A | Indoline compounds and derivatives as EGFR inhibitors | 百济神州有限公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2022063106-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEIGENE, LTD. (KY) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | MAP4K1 171/4885MAPK3 250/4885ALK 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.